• citations in SCIndeks: [1]
  • citations in CrossRef:0
  • citations in Google Scholar:[]
  • visits in previous 30 days:7
  • full-text downloads in 30 days:2


article: 3 from 3  
Back back to result list
2014, vol. 33, iss. 4, pp. 347-355
C-reactive protein predicts progression of peripheral arterial disease in patients with type 2 diabetes: A 5-year follow-up study
aClinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade
bClinical Center of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade + University of Belgrade, Faculty of Medicine
cInstitute for Gerontology and Palliative Care, Belgrade
dClinical Center of Serbia, Clinic for Cardiology, Belgrade
eClinical Center of Serbia, Clinic for Pulmonology, Belgrade
Insulin resistance: comparison of the role in onset and progression of type 2 diabetes, atherosclerotic vascular disease and neurodegenerative disorders (MESTD - 175097)
Biomarkers of organ damage and dysfunction (MESTD - 175036)

Background: Previous studies have indicated that high sensitivity C-reactive protein (hs-CRP) is a risk factor for the peripheral arterial disease (PAD) in diabetes. This study aimed to evaluate the possible predictive significance of hsCRP for the development and progression of PAD in patients with type 2 diabetes (T2D). Methods: The study included 80 patients previously diagnosed with T2D, aged 45-70 years, divided into group A (T2D patients with PAD; n = 38) and group B (T2D patients without PAD; n=42). After five years, all the patients were re-examined and divided into subgroups depending on de novo development of PAD or progression of previously diagnosed PAD. Ankle-Brachial Index (ABI) measurement was used for PAD diagnosis and hs-CRP was determined by nephelometry. Results: We found significantly higher hs-CRP levels in group A compared to group B, but only at baseline. Among the patients in group A, those with later progression of PAD (subgroup A1) had the highest levels of hs-CRP at baseline, although not significantly different from those in subgroup A2 (non-progressors). In contrast, hs-CRP level was significantly higher in subgroup B1 (progressors) in comparison to subgroup B2 (non-progressors) at both the first and second exam. Of all the investigated metabolic parameters, hs-CRP was the only independent predictor of PAD progression (OR=0.456, 95% CI=0.267-0.7815, p=0.004). The cut-off point for hs-CRP was 2.5 mg/L (specificity 75% and sensitivity 73.3%) with the relative risk for PAD of 2.93 (95% CI= 1.351-6.3629). Conclusions: Our study implies that hs-CRP can be used as a reliable predictor for the progression of PAD in patients with T2D.
*** (2001) The PARTNERS program: A national survey of peripheral arterial disease detection, awareness, and treatment. JAMA, 286: 1317-24
Aboyans, V., Criqui, M.H., Denenberg, J.O., Knoke, J.D., Ridker, P.M., Fronek, A. (2006) Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation, 113(22): 2623-9
Blake, G.J., Ridker, P.M. (2002) Inflammatory bio-markers and cardiovascular risk prediction. Journal of Internal Medicine, 252(4): 283-294
Britton, K.A., Mukamal, K.J., Ix, J.H., Siscovick, D.S., Newman, A.B., de Boer, I.H., Thacker, E.L., Biggs, M.L., Gaziano, J. M., Djoussé, L. (2012) Insulin resistance and incident peripheral artery disease in the Cardiovascular Health Study. Vascular Medicine, 17(2): 85-93
Campbell, M.J., Swinscow, T.D.V., ur. (2002) Statistics at square one 2002. London: Wiley-Blackwell, BMJ Books, pp. 111-145
Diehm, C., Allenberg, J.R., Pittrow, D., et al. (2009) German Epidemiological Trial on Ankle Brachial Index Study Group: Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation, 120: 2053-61
Eknoyan, G. (2008) Adolphe Quetelet (1796-1874): The average man and indices of obesity. Nephrol Dial Transplant, 23: 47-51
Fowkes, F.G.R., Housley, E., Cawood, E.H.H., Macintyre, C.C.A., Ruckley, C.V., Prescott, R.J. (1991) Edinburgh Artery Study: Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. International Journal of Epidemiology, 20(2): 384-392
Goldhaber, S.Z. (2009) European Atherosclerosis Society screening recommendations for lipoprotein (a) and high-sensitivity C-reactive protein: Double standard or failure of evidence-based medicine. Clinical Chemistry, 55: 378-84
Haffner, S.M., Kennedy, E., Gonzalez, C., Stern, M.P., Miettinen, H. (1996) A prospective analysis of the HOMA model: The Mexico City Diabetes Study. Diabetes Care, 19(10): 1138-1141
Haffner, S.M., Miettinen, H., Stern, M.P. (1997) The homeostasis model in the San Antonio Heart Study. Diabetes Care, 20(7): 1087-1092
Hozawa, A., Ohmori, K., Kuriyama, S., Shimazu, T., Niu, K., Watando, A., Ebihara, S., Matsui, T., Ichiki, M., Nagatomi, R., Sasaki, H., Tsuji, I. (2004) C-reactive protein and peripheral artery disease among Japanese elderly: The Tsurugaya Project. Hypertension Research, 27(12): 955-961
Hull, S.K., Kishman, C.R. J. (2008) What is the best test for peripheral vascular disease?. J Fam Practice, 57: 403-5
Kaptoge, S., di Angelantonio, E., Lowe, G., Pepys, M.B., Thompson, S.G., Collins, R., Danesh, J. (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet, 375(9709): 132-140
Korita, I., Bulo, A., Langlois, M., Blaton, V. (2013) Inflammation markers in patients with cardiovascular disease and metabolic syndrome. Journal of Medical Biochemistry, vol. 32, br. 3, str. 214-219
Leng, G.C., Lee, A.J., Fowkers, F.G.R., Whiteman, M., Dunbar, J., Housley, E., Ruckley, C.V. (1996) Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. International Journal of Epidemiology, 25(6): 1172-1181
Makin, A., Lip, G.Y.H., Silverman, S., Beevers, D.G. (2001) Peripheral vascular disease and hypertension: A forgotten association?. Journal of Human Hypertension, 15(7): 447-454
Mancia, G., Fagard, R., Narkiewicz, K., et al. (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 34:2159-219
Marso, S.P., Hiatt, W.R. (2006) Peripheral arterial disease in patients with diabetes. Journal of the American College of Cardiology, 47(5): 921-929
Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C. (1985) Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28(7): 412-419
Mcdermott, M.M., Guralnik, J.M., Greenland, P., Green, D., Liu, K., Ridker, P.M., Chan, C., Criqui, M.H., Ferrucci, L., Taylor, L.M., Pearce, W.H., Schneider, J.R., Oskin, S.I. (2004) Inflammatory and thrombotic blood markers and walking-related disability in men and women with and without peripheral arterial disease. Journal of the American Geriatrics Society, 52(11): 1888-1894
Mcdermott, M.M., Greenland, P., Green, D., Guralnik, J.M., Criqui, M.H., Liu, K., Chan, C., Pearce, W.H., Taylor, L., Ridker, P.M., Schneider, J.R., Martin, G., Rifai, N., Quann, M., Fornage, M. (2003) D-Dimer, inflammatory markers, and lower extremity functioning in patients with and without peripheral arterial disease. Circulation, 107(25): 3191-3198
Murabito, J.M., D'agostino, R.B., Silbershatz, H., Wilson, W.F. (1997) Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation, 96(1): 44-9
National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) (2000) The practical guide: Identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication, 4: 7-23, 00-4084
Nilsson, J. (2005) CRP: Marker or maker of cardiovascular disease?. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(8): 1527-1528
Pande, R.L., Perlstein, T.S., Beckman, J.A., Creader, M.A. (2008) Association of insulin resistance and inflammation with peripheral arterial disease: The National Health and Nutrition Examination Survey, 1999 to 2004. Circulation, 118: 33-41
Pearson, T.A., Mensah, G.A., Alexander, R. W., Anderson, J.L., Cannon, R.O. I., Criqui, M., Fadl, Y.Y., Fortmann, S.P., Hong, Y., Myers, G.L., Rifai, N., Smith, S.C., Taubert, K. (2003) Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107(3): 499-511
Ridker, P.M. (2001) High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation, 103(13): 1813-8
Ridker, P.M., Cushman, M., Stampfer, M.J., Tracy, R.P., Hennekens, C.H. (1998) Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation, 97(5): 425-428
Romero-Corral, A., Somers, V.K., Sierra-Johnson, J., Thomas, R.J., Collazo-Clavell, M.L., Korinek, J., Allison, T.G., Batsis, J.A., Sert-Kuniyoshi, F.H., Lopez-Jimenez, F. (2008) Accuracy of body mass index in diagnosing obesity in the adult general population. International Journal of Obesity, 32(6): 959-966
Selvin, E., Erlinger, T.P. (2004) Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation, 110, str. 738-43
Signorelli, S.S., Fiore, V., Malaponte, G. (2014) Inflammation and peripheral arterial disease: The value of circulating biomarkers. International Journal of Molecular Medicine, 33(4): 777-783
Vainas, T., Stassen, F.R.M., de Graaf, R., Twiss, E.L.L., Herngreen, S.B., Welten, R.J.Th. J., van den Akker, L.H.J.M., van Dieijen-Visser, M.P., Bruggeman, C.A., Kitslaar, P.J.E.H.M. (2005) C-reactive protein in peripheral arterial disease: Relation to severity of the disease and to future cardiovascular events. Journal of Vascular Surgery, 42(2): 243-251
van der Meer, I.M., Oei, H.S., Hofman, A., Pols, H.A.P., de Jong, F.H., Witteman, J.C.M. (2006) Soluble Fas, a mediator of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis: The Rotterdam Coronary Calcification Study. Atherosclerosis, 189(2): 464-469
Wallace, T.M., Levy, J.C., Matthews, D.R. (2004) Use and abuse of HOMA modeling. Diabetes Care, 27(6): 1487-1495
Wallenstein, S., Wittes, J. (1993) The power of the Mantel-Haenszel test for grouped failure time data. Biometrics, 49(4): 1077-1097
Willerson, J.T., Cohn, J.N., Wellens, H.J.J., Holmes, D.R. J., ur. (2007) Cardiovascular medicine 2. London: Springer, 1681-703
Williams, J.R. (2008) The Declaration of Helsinki and public health. Bulletin of the World Health Organization, 86(8): 650-651


article language: English
document type: Original Scientific Paper
DOI: 10.2478/jomb-2014-0042
published in SCIndeks: 17/01/2020